Lisa R. Sammaritano, MD


Dr. Lisa Sammaritano joined Hospital for Special Surgery in 1988, when she began her fellowship in rheumatic diseases. She maintains a busy clinical practice and participates in clinical research geared towards patients with Systemic Lupus Erythematosus (SLE) and Antiphospholipid Antibodies. She has a particular interest and expertise in reproductive issues in rheumatic disease patients, including contraception and pregnancy.

Appointments

Associate Attending Physician, Hospital for Special Surgery
Associate Professor of Clinical Medicine, Weill Cornell Medical College

Specialty

Special Expertise

Systemic Lupus Erythematosus (SLE)
Pregnancy and Rheumatic Diseases
Hormones in Rheumatic Diseases
Antiphospholipid Antibody

Awards

Alpha Omega Alpha Medical Honor Society
Phi Beta Kappa Honor Society

Specialized Centers

Education

BA, University of Pennsylvania, Philadelphia, Pennsylvania, 1981
MD, Weill Cornell Medical College, New York, 1985

Residency

Weill Cornell Medical College, Internal Medicine, 1985-88

Fellowship

Weill Cornell Medical College, Rheumatology, 1988-91

Certification

Internal Medicine, 1988
Rheumatology, 1990

State Licensure

New York

Lisa R. Sammaritano, MD has contributed to the following articles on HSS.edu:

Selected Publications

For more publications, please see the PubMed listing.

Research Description

Antiphospholipid Antibodies: Mechanisms and Risk Factors for Thrombosis

Antiphospholipid antibodies (aPL) are associated with a clinical syndrome which includes recurrent arterial and venous thromboses, recurrent fetal loss, thrombocytopenia and other complications. The mechanism of action of these autoantibodies has not been well defined. It is clear that most aPL bind to a cryptic epitope on a normal plasma glycoprotein, Beta 2-glycoprotein I, when this glycoprotein is bound to phospholipid.

Our recent work has shown activation of cultured human vein endothelial cells (HUVEC) by IgG from patients with anticardiolipin antibodies (aCL). Incubation with aCL IgG produced a 7-fold increase in monocyte adhesion compared with incubation with IgG from normal controls. Immunofluorescent microscopy demonstrated increased expression of cell adhesion molecules including E selectin, VCAM-1, and I CAM - 1.

We have also investigated possible contributors to aPL risk, or "second hit" factors. We have identified presence of IgG2 subclass of aCL to be associated with clinical risk of thrombosis. Presence of factor V Leiden is more common in aCL patients with as compared to without thrombosis. Finally, we continue to investigate other potential genetic or environmental risk factors, including FcRIIa allelic variation and homcysteinemia.

Safety of Estrogens in Lupus Erythematosus, National Assessment (SELENA)

The safety of exogenous estrogens in systemic lupus has been widely questioned, with several case reports and one retrospective study suggesting an increased risk of flare associated with oral contraceptive use. Because of the potential benefits of oral contraceptives and hormone replacement therapy, we are conducting a nationwide multicenter randomized placebo-controlled double blind study to evaluate the safety of these preparations in patients with stable or inactive SLE. Hospital for Special Surgery is one of 5 centers participating in this NIH funded project, which may change practice patterns if safety of estrogens is shown.

Clinical Trials

^ Back to Top
Dr. Lisa Sammaritano, Rheumatologist, Internist

Contact Information

Office Locations

Hospital for Special Surgery
8th Floor
535 East 70th Street
New York, NY 10021

Tel: 212.606.1978
Fax: 212.774.2258

Burke Rehabilitation Office
785 Mamaroneck Avenue
White Plains, NY 10605

Mailing Address

Hospital for Special Surgery
535 East 70th Street
New York, New York 10021

Patient Stories: